shutterstock_557097946 - Clinical Trials Arena
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Previously approved IDH2 inhibitor seeks label expansion in acute myeloid leukaemia

The Celgene trial was the first to demonstrate a benefit in the front-line setting for patients who are ineligible for intensive chemotherapy.